{"id":14978,"date":"2015-07-21T10:40:26","date_gmt":"2015-07-21T09:40:26","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=14978"},"modified":"2015-07-21T10:40:26","modified_gmt":"2015-07-21T09:40:26","slug":"esclerosi-multiple-quins-son-els-nous-tractaments","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","title":{"rendered":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?"},"content":{"rendered":"<p>L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que<strong> afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa<\/strong>. <strong>A Espanya<\/strong>, es calcula que n\u2019estan afectades al voltant de <strong>46.000 persones, 7.000 a Catalunya<\/strong>. En els \u00faltims anys han aparegut nous medicaments per al tractament de l\u2019EM i, en conseq\u00fc\u00e8ncia, s\u2019han obert noves portes per conviure amb la malaltia de la millor manera possible. Aquests medicaments aporten aven\u00e7os en el tractament i millores en la qualitat de vida dels pacients afectats. La \u00faltima aprovaci\u00f3 de l\u2019EMA (European Medicines Agency) i la imminent disponibilitat per als pacients de Catalunya d\u2019aquests nous f\u00e0rmacs, ha fet convenient una revisi\u00f3 i una valoraci\u00f3 de com quedar\u00e0 el mapa actual i futur de l\u2019EM.<\/p>\n<div class=\"box shadow\">\u201cEl tractament s\u2019ha concentrat b\u00e0sicament en l\u2019interfer\u00f3 beta 1b, l\u2019interfer\u00f3 beta 1a, l\u2019acetat de glatir\u00e0mer, el natalizumab, el fingolimod i la mitoxantrona, medicaments aprovats i utilitzats com a tractaments modificadors de l\u2019esclerosi m\u00faltiple amb els seus avantatges i inconvenients. <strong>Darrerament s\u2019han comercialitzat, o estan a punt de fer-ho, nous medicaments per via oral com el laquinimod, la teriflunomida i el dimetil-fumarat que ofereixen avantatges en la seva administraci\u00f3 oral, efic\u00e0cia comparable i efectes adversos individualitzats, la qual cosa far\u00e0 que l\u2019elecci\u00f3 del tractament sigui clarament personalitzada<\/strong>\u201d explica Tom\u00e0s Casasin, vocal d\u2019Hospitals del COFB i coordinador de l\u2019activitat.<\/div>\n<figure id=\"attachment_14990\" aria-describedby=\"caption-attachment-14990\" style=\"width: 221px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-4.jpg\"><img decoding=\"async\" class=\" wp-image-14990       \" alt=\"novetats-esclerosi-multiple (4)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-4.jpg\" width=\"221\" height=\"149\" \/><\/a><figcaption id=\"caption-attachment-14990\" class=\"wp-caption-text\">Sergio Mart\u00ednez, neur\u00f2leg cap de secci\u00f3 i responsable de la Unitat d\u2019Esclerosi M\u00faltiple de l\u2019Hospital Universitari Bellvitge<\/figcaption><\/figure>\n<p>Per aprofundir en el coneixement de les noves ter\u00e0pies per combatre l\u2019EM, con\u00e8ixer els aspectes cient\u00edfics m\u00e9s rellevants dels nous f\u00e0rmacs i revisar la situaci\u00f3 farmacoterap\u00e8utica actual i el futur dels tractaments, com tamb\u00e9 donar a con\u00e8ixer l\u2019an\u00e0lisi farmacoecon\u00f2mica dels tractaments actuals, el Col\u00b7legi, conjuntament amb Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC), van organitzar el 4 de juny la confer\u00e8ncia \u201cNous tractaments de l\u2019esclerosi m\u00faltiple\u201d, adre\u00e7ada a farmac\u00e8utics d\u2019hospital, d\u2019atenci\u00f3 prim\u00e0ria i administraci\u00f3 sanit\u00e0ria.<\/p>\n<figure id=\"attachment_14988\" aria-describedby=\"caption-attachment-14988\" style=\"width: 224px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-2.jpg\"><img decoding=\"async\" class=\" wp-image-14988    \" alt=\"novetats-esclerosi-multiple (2)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-2.jpg\" width=\"224\" height=\"150\" \/><\/a><figcaption id=\"caption-attachment-14988\" class=\"wp-caption-text\">Albert Saiz, neur\u00f2leg responsable de la Unitat d\u2019Esclerosi M\u00faltiple de l\u2019Hospital Cl\u00ednic Barcelona<\/figcaption><\/figure>\n<p>Per tractar d\u2019aquests temes, el doctor Albert Saiz, neur\u00f2leg responsable de la Unitat d\u2019Esclerosi M\u00faltiple de l\u2019Hospital Cl\u00ednic Barcelona, i el doctor Sergio Mart\u00ednez, neur\u00f2leg cap de secci\u00f3 i responsable de la Unitat d\u2019Esclerosi M\u00faltiple de l\u2019Hospital Universitari Bellvitge, varen presentar la situaci\u00f3 actual del tractament de l\u2019esclerosi m\u00faltiple i analitzar l&#8217;aparici\u00f3 dels nous tractaments. \u201cUn dels punts m\u00e9s interessants fou el <strong>diferenciar entre els efectes sobre la disminuci\u00f3 dels brots de la malaltia, les lesions inflamat\u00f2ries en resson\u00e0ncia, per\u00f2, sobretot, la variable principal com \u00e9s el grau de depend\u00e8ncia dels pacients<\/strong>\u201d concreta Casasin. Despr\u00e9s d\u2019aquestes intervencions, es va obrir un interessant debat moderat per Julio Mart\u00ednez, president de la Societat Catalana de Farm\u00e0cia Cl\u00ednica.<\/p>\n<figure id=\"attachment_14987\" aria-describedby=\"caption-attachment-14987\" style=\"width: 221px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-1.jpg\"><img decoding=\"async\" class=\" wp-image-14987    \" alt=\"novetats-esclerosi-multiple (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-1.jpg\" width=\"221\" height=\"148\" \/><\/a><figcaption id=\"caption-attachment-14987\" class=\"wp-caption-text\">Pere Ventanyol, farmac\u00e8utic cap de secci\u00f3 de l\u2019Hospital Universitari de Son Espases<\/figcaption><\/figure>\n<p>Per \u00faltim, Pere Ventanyol, farmac\u00e8utic cap de secci\u00f3 de l\u2019Hospital Universitari de Son Espases, va parlar abastament dels informes de posicionament terap\u00e8utic del Ministeri de Sanitat amb les mancances d\u2019avaluacions farmacoecon\u00f2miques clares i tamb\u00e9 de la import\u00e0ncia de l\u2019an\u00e0lisi de n\u00famero de pacients a tractar (NNT) en aquestes an\u00e0lisis. Aix\u00ed mateix, va aprofundir en el concepte d\u2019anys de vida guanyats de qualitat (AVAQ) com a model econ\u00f2mic m\u00e9s sofisticat per\u00f2 que d\u00f3na resposta a les dades d\u2019efectivitat de les intervencions sanit\u00e0ries aplicades a una determinada poblaci\u00f3.<\/p>\n<p>&nbsp;<\/p>\n<figure id=\"attachment_14991\" aria-describedby=\"caption-attachment-14991\" style=\"width: 468px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-5.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-14991  \" alt=\"novetats-esclerosi-multiple (5)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/novetats-esclerosi-multiple-5.jpg\" width=\"468\" height=\"312\" \/><\/a><figcaption id=\"caption-attachment-14991\" class=\"wp-caption-text\">D&#8217;esquerra a dreta: Tom\u00e0s Casasin (COFB), Sergio Mart\u00ednez, Albert Saiz, Julio Mart\u00ednez (SCFC) i Pere Ventanyol<\/figcaption><\/figure>\n<p style=\"text-align: right;\">\u00a0<b>Amb la col\u00b7laboraci\u00f3 de:<\/b><\/p>\n<p align=\"right\"><a href=\"http:\/\/www.genzyme.es\/ \" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright  wp-image-14980\" alt=\"genzyme\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2015\/07\/genzyme.jpg\" width=\"158\" height=\"112\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa. A Espanya, es calcula que n\u2019estan afectades al voltant de 46.000 persones, 7.000 a Catalunya. En els \u00faltims anys han aparegut nous medicaments [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":14989,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[938,2221,215,480],"class_list":["post-14978","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-atencio-primaria","tag-em","tag-esclerosi-multiple","tag-farmacia-hospitalaria"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa. A Espanya, es calcula que n\u2019estan afectades al voltant de 46.000 persones, 7.000 a Catalunya. En els \u00faltims anys han aparegut nous medicaments [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-21T09:40:26+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?\",\"datePublished\":\"2015-07-21T09:40:26+00:00\",\"dateModified\":\"2015-07-21T09:40:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\"},\"wordCount\":705,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Atenci\u00f3 prim\u00e0ria\",\"EM\",\"esclerosi m\u00faltiple\",\"farm\u00e0cia hospital\u00e0ria\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\",\"name\":\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2015-07-21T09:40:26+00:00\",\"dateModified\":\"2015-07-21T09:40:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","og_locale":"ca_ES","og_type":"article","og_title":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa. A Espanya, es calcula que n\u2019estan afectades al voltant de 46.000 persones, 7.000 a Catalunya. En els \u00faltims anys han aparegut nous medicaments [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2015-07-21T09:40:26+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?","datePublished":"2015-07-21T09:40:26+00:00","dateModified":"2015-07-21T09:40:26+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/"},"wordCount":705,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage"},"thumbnailUrl":"","keywords":["Atenci\u00f3 prim\u00e0ria","EM","esclerosi m\u00faltiple","farm\u00e0cia hospital\u00e0ria"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","url":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/","name":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage"},"thumbnailUrl":"","datePublished":"2015-07-21T09:40:26+00:00","dateModified":"2015-07-21T09:40:26+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2015\/07\/21\/esclerosi-multiple-quins-son-els-nous-tractaments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Esclerosi m\u00faltiple: quins s\u00f3n els nous tractaments?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia autoimmune del sistema nervi\u00f3s central que afecta m\u00e9s de 2 milions de persones a tot el m\u00f3n, aproximadament 630.000 a Europa. A Espanya, es calcula que n\u2019estan afectades al voltant de 46.000 persones, 7.000 a Catalunya. En els \u00faltims anys han aparegut nous medicaments [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/14978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=14978"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/14978\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=14978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=14978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=14978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}